- Home
- H vs NBIX Comparison
H vs NBIX Comparison
Compare H & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- H
- NBIX
- Stock Information
- Founded
- H 1957
- NBIX 1992
- Country
- H United States
- NBIX United States
- Employees
- H N/A
- NBIX N/A
- Industry
- H Hotels/Resorts
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- H Consumer Discretionary
- NBIX Health Care
- Exchange
- H Nasdaq
- NBIX Nasdaq
- Market Cap
- H 13.2B
- NBIX 12.3B
- IPO Year
- H 2009
- NBIX 1996
- Fundamental
- Price
- H $141.12
- NBIX $132.90
- Analyst Decision
- H Buy
- NBIX Strong Buy
- Analyst Count
- H 18
- NBIX 19
- Target Price
- H $152.11
- NBIX $162.42
- AVG Volume (30 Days)
- H 1.0M
- NBIX 1.1M
- Earning Date
- H 08-07-2025
- NBIX 07-30-2025
- Dividend Yield
- H 0.43%
- NBIX N/A
- EPS Growth
- H N/A
- NBIX 2.97
- EPS
- H 4.36
- NBIX 3.39
- Revenue
- H $3,218,000,000.00
- NBIX $2,509,900,000.00
- Revenue This Year
- H $114.05
- NBIX $16.12
- Revenue Next Year
- H $5.29
- NBIX $15.06
- P/E Ratio
- H $32.39
- NBIX $39.19
- Revenue Growth
- H N/A
- NBIX 18.42
- 52 Week Low
- H $102.43
- NBIX $84.23
- 52 Week High
- H $168.20
- NBIX $154.87
- Technical
- Relative Strength Index (RSI)
- H 49.36
- NBIX 57.20
- Support Level
- H $134.00
- NBIX $123.67
- Resistance Level
- H $145.29
- NBIX $129.35
- Average True Range (ATR)
- H 3.96
- NBIX 3.45
- MACD
- H -0.03
- NBIX 0.11
- Stochastic Oscillator
- H 49.07
- NBIX 67.03
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.